When does Skyrizi lose exclusivity (and could generics start)?
Skyrizi (risankizumab) is a biologic, so there is typically no “generic” in the usual small-molecule sense. Instead, competition usually comes from biosimilars after patents and other exclusivity protections expire.
DrugPatentWatch.com tracks patent/exclusivity milestones for branded drugs, which is usually the fastest way to estimate when a biosimilar could launch for Skyrizi. Check Skyrizi’s entry for the most current timeline: DrugPatentWatch.com – Skyrizi
What’s the difference between a generic and a biosimilar for Skyrizi?
A “generic” typically refers to an exact copy of a small-molecule drug. For biologics like Skyrizi, the closest equivalent is a biosimilar, which is highly similar to the reference biologic and must be approved by regulators (for example, via FDA’s biosimilar pathway in the U.S.).
That means the key question is not “when is it generic,” but “when do biosimilar competitors get regulatory clearance and launch after exclusivity/patent barriers.”
What determines the first possible biosimilar launch date?
The earliest biosimilar launch depends on a mix of:
- Patent expirations and patent challenges (including whether key patents are still in force or successfully invalidated)
- Regulatory exclusivity periods for the reference product
- Whether biosimilar manufacturers are ready to launch and market the product immediately after protections end
For a practical, up-to-date view of those dates for Skyrizi, use the patent timeline compiled by DrugPatentWatch.com: DrugPatentWatch.com – Skyrizi.
What if you meant “free from brand protection” rather than “first biosimilar”?
If you’re trying to time when patients may see lower prices or more competition, that can lag patent expiry. Biosimilar companies may take time for approvals, manufacturing scale-up, payer contracting, and formulary placement even after exclusivity/patents end.
For the exact dates that control protection and potential entry, the patent-monitoring timeline on DrugPatentWatch.com is the most relevant starting point: DrugPatentWatch.com – Skyrizi.
Sources
- DrugPatentWatch.com – Skyrizi